Imaging Tests for Cancer: CT, MRI, PET, and More

Imaging tests for cancer are the tools that allow clinicians to see inside the body without surgery — to find suspicious lesions, determine how far cancer has spread, and assess whether treatment is working. But none of the imaging tests used in oncology can diagnose cancer alone. Every imaging finding described as “suspicious for malignancy” requires tissue biopsy for confirmation before treatment begins.

Seven major imaging modalities are used in oncology: X-ray, CT, MRI, PET scan, ultrasound, bone scan, and mammography. Each uses a different physical principle to produce images of body structures, and each has specific clinical strengths and appropriate indications. Understanding which imaging tests for cancer are ordered — and why — can help you make sense of the diagnostic process. For how imaging and blood work together in the cancer workup, see our overview of cancer blood tests.

What Imaging Tests for Cancer Do — and Don’t Do

Imaging tests for cancer generate probability — not certainty. Radiology reports use standardized risk classification systems to communicate that probability:

• BI-RADS (breast imaging): 1–6 scale; BI-RADS 4 = suspicious, biopsy recommended
• LI-RADS (liver in cirrhosis): 1–5 scale; LI-RADS 5 = highly suspicious for HCC
• PI-RADS (prostate MRI): 1–5 scale; PI-RADS 4–5 = targeted biopsy recommended
• ACR TI-RADS (thyroid ultrasound): 1–5 scale guiding FNA biopsy decisions

RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) is the standard framework for measuring tumor response to treatment on CT or MRI. A ≥30% decrease in the sum of target lesion diameters = partial response. A ≥20% increase = progressive disease. These terms appear in oncology reports and clinical trial results.

Imaging Tests for Cancer — CT Scan

CT (computed tomography) is the most widely ordered of all imaging tests for cancer. It uses multiple X-ray projections processed by computer into detailed cross-sectional images of the entire body in minutes.

CT for Lung Cancer Screening

The USPSTF (2021, Grade B) recommends annual low-dose CT (LDCT) for adults aged 50–80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. The NLST trial (NEJM 2011) showed LDCT reduced lung cancer mortality by 20% vs. chest X-ray. The European NELSON trial (NEJM 2020) showed 24% mortality reduction in men and 33% in women. LDCT uses approximately 1–2 mSv — significantly less radiation than a standard diagnostic CT (8–14 mSv).

CT for Staging and Monitoring

Contrast-enhanced CT with iodinated IV contrast is the workhorse for staging most solid tumors: lung, colorectal, pancreatic, renal, gastric, and bladder cancer. Different contrast phases capture different tumor types — arterial phase (25–30 seconds) for hypervascular tumors (HCC, renal cell); portal venous phase (60–70 seconds) for most metastases.

In cirrhotic patients, a liver lesion ≥1 cm showing arterial hyperenhancement with venous washout is classified LI-RADS 5 — treated as HCC without biopsy in appropriate clinical protocols. CT colonography (virtual colonoscopy) achieves 96% sensitivity for polyps ≥10 mm (ACRIN 6664 trial) without sedation, though any positive finding requires optical colonoscopy follow-up.

Imaging Tests for Cancer — MRI

MRI uses radiofrequency pulses within a strong magnetic field to generate images based on hydrogen atom behavior in tissues. It produces outstanding soft tissue contrast and carries no ionizing radiation.

Brain Tumors

MRI with gadolinium is the gold standard for brain tumor imaging. Contrast enhancement identifies areas of blood-brain barrier breakdown (active tumor). Diffusion-weighted imaging (DWI) characterizes cellularity. MR spectroscopy adds metabolic profiling (elevated choline/creatinine ratio = tumor). MRI also distinguishes tumor recurrence from radiation necrosis — a distinction CT cannot reliably make.

Prostate — Multiparametric MRI (mpMRI)

mpMRI combines T2-weighted imaging (anatomy), DWI (cellularity), and dynamic contrast enhancement (vascularity) into a comprehensive prostate cancer evaluation. Results are scored on the PI-RADS scale (1–5). The PROMIS trial (Lancet 2017) showed mpMRI sensitivity of 93% for clinically significant prostate cancer — substantially better than systematic biopsy alone. AUA, NCCN, and EAU guidelines recommend mpMRI before prostate biopsy when available. Targeted MRI/ultrasound fusion biopsy of PI-RADS 4–5 lesions reduces overdiagnosis of insignificant cancers while improving detection of significant ones.

Breast MRI and Other Applications

ACS recommends annual breast MRI alongside mammography for women with lifetime breast cancer risk ≥20–25%, including BRCA1/2 carriers. Breast MRI sensitivity is 77–90% in high-risk women — higher than mammography but with more false positives, requiring careful patient selection.

MRI is also the most accurate tool for rectal cancer local staging (T stage, mesorectal fascia involvement, lymph nodes — guiding preoperative radiation and surgical planning), and for sarcoma extent assessment (neurovascular involvement, bone marrow infiltration).

Imaging Tests for Cancer — PET-CT

PET uses radioactive glucose (F-18 FDG) to image metabolic activity. Cancer cells are hypermetabolic — they take up significantly more glucose — appearing as bright “hot spots.” PET is always combined with CT (PET-CT) in modern practice: CT provides anatomy; PET maps metabolism.

Where PET-CT excels:

• Lymphoma: FDG-avid lymphomas (Hodgkin’s, DLBCL) are ideally imaged by PET. Deauville scale (1–5) scores response: 1–2 = complete metabolic response; 4–5 = residual disease. Interim PET after 2 ABVD cycles in Hodgkin’s guides escalation or de-escalation (RATHL trial)
• Lung cancer: Initial staging, mediastinal lymph node assessment, treatment response, recurrence
• Colorectal cancer recurrence: CEA-directed restaging; detects hepatic, pulmonary, pelvic relapse
• Esophageal and gastric cancer: Staging and neoadjuvant response
• Head and neck cancer: Initial staging, treatment response, recurrence

Specialized PET tracers beyond FDG:

• PSMA PET (Ga-68 or F-18, FDA-approved 2020–2021): Detects prostate cancer recurrence even at PSA 0.2–2.0 ng/mL — a range where conventional CT and bone scan are insensitive. Now incorporated into major prostate cancer guidelines.
• Ga-68 DOTATATE PET: Gold standard for neuroendocrine tumor staging. Superior whole-body sensitivity vs. CT alone or octreotide scintigraphy.

Mammography — Breast Cancer Screening Standard

Mammography is the only imaging test with demonstrated breast cancer mortality reduction from randomized controlled trials. The USPSTF (2024) recommends mammography screening every other year starting at age 40 (Grade B). The American Cancer Society recommends annual mammography starting at 40.

Digital breast tomosynthesis (DBT/3D mammography) takes multiple low-dose images at different angles reconstructed into thin slices, reducing the tissue overlap that causes false-positive recalls. DBT detects approximately 20–30% more invasive cancers than 2D mammography while reducing recall rates by 15–25%.

Women with extremely dense breasts have reduced mammography sensitivity and may benefit from supplemental ultrasound or breast MRI screening. BI-RADS 4 (suspicious) findings prompt biopsy; BI-RADS 3 (probably benign, <2% malignancy risk) typically warrants 6-month follow-up imaging.

Ultrasound — Real-Time, Radiation-Free

Ultrasound uses high-frequency sound waves to produce real-time images without ionizing radiation. It is the most widely available of the imaging tests for cancer — and the most operator-dependent.

Cancer applications:

• Breast: Characterizes mammographic findings (solid vs. cystic); guides core needle biopsy in real time
• Thyroid: First-line imaging for nodules; ACR TI-RADS scoring guides FNA decisions
• Liver: HCC surveillance in cirrhosis/chronic HBV — every 6 months with AFP (sensitivity ~63% at expert centers)
• Testicular masses: First-line imaging; intratesticular solid masses are malignant until proven otherwise

Limitations: operator-dependent; cannot evaluate lungs or structures behind bone; limited by bowel gas for deep abdominal structures.

Bone Scan and Nuclear Medicine

Technetium-99m MDP bone scan detects areas of high bone turnover — osteoblastic metastases appear as “hot spots.” Used for screening bone metastases in prostate, breast, and lung cancers. SPECT-CT (combined with CT) improves localization vs. planar imaging.

Key limitations: Hot spots occur with arthritis, fractures, and infection (non-specific). Multiple myeloma produces purely lytic lesions with minimal osteoblastic response — bone scan is unreliable for myeloma; whole-body MRI or PET-CT is preferred. PSMA PET has replaced conventional bone scan for prostate cancer restaging in many centers; Ga-68 DOTATATE PET has replaced octreotide scintigraphy for neuroendocrine tumors.

Choosing the Right Imaging Test for Cancer

For a detailed look at what happens during a CT scan — preparation, contrast, what the report means — see our dedicated guide to the CT scan for cancer. For how imaging leads to biopsy, see our biopsy for cancer guide. If you’re still in the symptom-evaluation stage, our cancer symptoms checklist explains which symptoms typically prompt imaging workup.

Frequently Asked Questions

This article is for educational purposes only and does not constitute medical advice. Imaging test selection should be discussed with your healthcare provider based on your specific clinical situation.